Blue Jet Healthcare share price
NSE: BLUEJETBSE: 544009Pharmaceuticals & BiotechnologySmall Cap
Blue Jet Healthcare Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2023 · Issue price ₹346
Last close ₹503.55down ₹14.30 (2.76%)BSE ₹503.85
Share price at the NSE close on 29 Oct 2026. Previous close ₹517.85.
29 Oct: open ₹517.10, high ₹528.30, low ₹498.10
52-week range of traded prices to 29 Oct 2026
₹325.00Low, 30 Mar 2026₹688.50High, 4 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,531 Cr645th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.24%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 18.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,94,14446.8% delivered
About Blue Jet Healthcare
Blue Jet Healthcare makes intermediates for the contrast media used in X-ray, CT and MRI scans, pharmaceutical intermediates and active pharmaceutical ingredients (APIs, the substances that make a medicine work), and high-intensity sweeteners such as saccharin.12 It sells to innovator and multinational generic drug companies and to consumer goods (FMCG) makers, from plants in Maharashtra.13
It works as a contract development and manufacturing organisation (CDMO, a firm that develops and makes products to other companies' orders).4 It sells in 3 product categories, contrast media intermediates, pharma intermediates and APIs, and high-intensity sweeteners, and reports them as a single business segment.56 Its saccharin and saccharin salts go into table-top sweeteners, oral care, beverages, confectionery, pharmaceuticals, food supplements and animal nutrition.7 It has no subsidiaries.8
Blue Jet Healthcare was established in 1968, has made high-intensity sweeteners since 1970 and began supplying contrast media intermediates in 2000.9710 The company says it was the first manufacturer of saccharin sodium in India.11 Its shares listed on BSE and NSE through an initial public offer (IPO) in 2023.12 The promoter group held 79.81% of the shares at 31 Mar 2026; Executive Chairman Akshay Bansarilal Arora is related to Managing Director Shiven Akshay Arora.131415
Blue Jet Healthcare key points
Results
- In the quarter to Jun 2026, revenue from operations was ₹2,931 million, EBITDA (earnings before interest, tax, depreciation and amortisation) ₹981 million and profit after tax ₹783 million.16
- Against the same quarter a year earlier, revenue fell 17%, EBITDA 19% and profit after tax 14%, as pharma intermediates and APIs sales dropped to ₹1,210 million from ₹2,120 million.17
- In the year to Mar 2026, revenue from operations fell 8% to ₹9,473 million and profit after tax fell 18.8% to ₹2,478 million. EBITDA was ₹2,940.99 million, a 31.0% margin.1819
- The company said it ended the year to Mar 2026 with no debt and about ₹350 crore in liquid assets, after ₹334 crore of operating cash flow in the year.20
Revenue mix
- Revenue by product category, year to Mar 202621Contrast media intermediates revenue grew 23% from the year before.
Item year to Mar 2026 Contrast media intermediates ₹495 crore Pharma intermediates and APIs ₹298 crore High-intensity sweeteners ₹131 crore - The company stated in its annual report for the year to Mar 2026 that customer forecasts indicate mid-single-digit growth for contrast media intermediates in the year to Mar 2027, and that it plans to launch 3 to 4 new products there.2223
- On its earnings call of 3 Aug 2026, the company said it restarted supply of a pharma intermediate hit by customer destocking (customers running down stock) and, given order visibility for that molecule, believes those sales can be sustained in the year to Mar 2027.24
Where revenue comes from
Plants and capacity
- Annual installed capacity in kilolitres (KL), 31 Mar 202627
Item year to Mar 2026 Ambernath (Unit II) 833.60 KL Shahad (Unit I) 200.60 KL Mahad (Unit III) 141.40 KL - On its earnings call of 3 Aug 2026, the company said it expects commercial contribution in the half year to Mar 2027 from its backward integration project at Mahad (Unit III), which is to make a key contrast media raw material in-house.2829
Customers and partners
- In the year to Mar 2026, 2 customers accounted for about 40.64% and 30.45% of revenue from product sales; a year earlier, 2 customers accounted for 41.44% and 34.05%.30
- Over 85% of total sales in the year to Mar 2026 were backed by contracted volumes under medium- and long-term supply contracts.31
- The company supplies contrast media intermediates directly to 3 contrast media manufacturers.32
- Pharma intermediates and APIs go to over 40 customers in India and 16 globally, across North America, Europe, Asia and Latin America.33
Research and development
- The research centre at Ambernath (Unit II) has 63 R&D professionals; R&D spending was ₹71.55 million in the year to Mar 2026.3435
- The company was tracking about 20 CDMO requests for proposals (RFPs); its high-priority pipeline held 6 Phase-3 (final-stage trial) programmes, among them 2 GLP-1 (diabetes and obesity drug) candidates and 1 contrast media new chemical entity (NCE, a new drug molecule), plus 2 commercial products.36
- The company stated in its annual report for the year to Mar 2026 that it is establishing an R&D centre in Hyderabad, over 57,240 sq. ft. on a 10-year lease, with planned investment of about ₹400 million, for enzymatic and chiral technologies and peptide fragments.3738
Expansion and capital spending
- In the year to Mar 2026, the company agreed to buy 102.48 acres of industrial land at Rambilli, Anakapalli District, Andhra Pradesh, from the state's industrial infrastructure corporation for ₹435.02 million.39
- The company stated in its annual report for the year to Mar 2026 that its board approved Phase 1 of the Vizag, Andhra Pradesh project, about ₹1,000 crore over 3 years, and that the site could take up to ₹2,300 crore subject to approvals.4041
- The company stated in its annual report for the year to Mar 2026 that the Vizag plant is slated to start operating in the year to Mar 2029, adding a proposed 1,000 KL of capacity.42
Recent events
- On 9 Jul 2026 the company raised ₹8,000 million in a qualified institutional placement (a share sale to large institutions), issuing 15,810,276 shares at ₹506 each; public shareholding rose to 26.85%, meeting the minimum public shareholding rule (a floor on the public's share).4344
- On 28 Feb 2026 the company held the ground-breaking of its Vizag manufacturing facility.45
- On 17 Dec 2025 the company disclosed that CARE Ratings had assigned its bank facilities credit ratings (an agency's view of its ability to repay debt) of CARE A+ with a stable outlook for the long term and CARE A1+ for the short term.46
Last updated
All 46 sources, each with its page
- 1. Annual report, 18 Aug 2026, page 7
- 2. Annual report, 18 Aug 2026, page 25
- 3. Annual report, 18 Aug 2026, page 10
- 4. Investor presentation, 3 Aug 2026, page 17
- 5. Investor presentation, 3 Aug 2026, page 18
- 6. Annual report, 18 Aug 2026, page 225
- 7. Annual report, 18 Aug 2026, page 29
- 8. Annual report, 18 Aug 2026, page 93
- 9. Annual report, 18 Aug 2026, page 7
- 10. Annual report, 18 Aug 2026, page 26
- 11. Annual report, 18 Aug 2026, page 30
- 12. Annual report, 18 Aug 2026, page 12
- 13. Annual report, 18 Aug 2026, page 90
- 14. Annual report, 18 Aug 2026, page 92
- 15. Annual report, 18 Aug 2026, page 42
- 16. Investor presentation, 3 Aug 2026, page 6
- 17. Investor presentation, 3 Aug 2026, page 7
- 18. Annual report, 18 Aug 2026, page 17
- 19. Investor presentation, 3 Aug 2026, page 18
- 20. Annual report, 18 Aug 2026, page 16
- 21. Annual report, 18 Aug 2026, page 16
- 22. Annual report, 18 Aug 2026, page 16
- 23. Annual report, 18 Aug 2026, page 26
- 24. Earnings call, 3 Aug 2026, page 6
- 25. Annual report, 18 Aug 2026, page 10
- 26. Annual report, 18 Aug 2026, page 100
- 27. Annual report, 18 Aug 2026, page 20
- 28. Earnings call, 3 Aug 2026, page 4
- 29. Annual report, 18 Aug 2026, page 26
- 30. Annual report, 18 Aug 2026, page 225
- 31. Annual report, 18 Aug 2026, page 26
- 32. Annual report, 18 Aug 2026, page 8
- 33. Annual report, 18 Aug 2026, page 27
- 34. Annual report, 18 Aug 2026, page 22
- 35. Annual report, 18 Aug 2026, page 69
- 36. Annual report, 18 Aug 2026, page 22
- 37. Annual report, 18 Aug 2026, page 16
- 38. Annual report, 18 Aug 2026, page 22
- 39. Annual report, 18 Aug 2026, page 5
- 40. Annual report, 18 Aug 2026, page 31
- 41. Annual report, 18 Aug 2026, page 14
- 42. Annual report, 18 Aug 2026, page 20
- 43. Annual report, 18 Aug 2026, page 60
- 44. Exchange filing, 9 Jul 2026, page 2
- 45. Annual report, 18 Aug 2026, page 31
- 46. Exchange filing, 17 Dec 2025, page 1
Results
Standalone; ₹ crore.Blue Jet Healthcare quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −27.5%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −34.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹293 Crup 24.91%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹78 Crup 21.63%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 26.7%
Revenue by quarter
Peak revenue ₹355 Cr, quarter to Jun 2025; lowest ₹165 Cr, quarter to Sep 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Net profit | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| Net margin | 28.0% | 31.1% | 32.3% | 25.7% | 31.5% | 20.9% | 27.4% | 26.7% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹947 Crdown 8.03%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹248 Crdown 18.80%
- Net margin
- 26.2%
Revenue by year
Peak revenue ₹1,030 Cr, year to Mar 2025; lowest ₹712 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 712 | 1,030 | 947 |
| Net profit | 164 | 305 | 248 |
| Net margin | 23.0% | 29.6% | 26.2% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical and API'S, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.Blue Jet Healthcare PE ratio and valuation
Price to earnings
At or below today's level on 42% of 601 trading days since May 2024.
LowestHighest
Its median44.92Industry median28.22
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 86% of 740 trading days over the last 3 years.
LowestHighest
Its median0.15%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −62.6% | −18.8% | −54.5% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
18 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 10 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 18 funds holding Blue Jet Healthcare
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 5
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 7
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 35
| Fund | |||
|---|---|---|---|
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 23,37,144 | 1.83% | ₹125.8 Cr |
| ICICI Prudential Value FundICICI Prudential Mutual Fund | 13,05,991 | 0.12% | ₹70.3 Cr |
| ICICI Prudential Manufacturing FundICICI Prudential Mutual Fund | 12,57,839 | 0.98% | ₹67.7 Cr |
 UTI Small Cap FundUTI Mutual Fund | 8,15,425 | 0.84% | ₹43.9 Cr |
 Groww Multicap FundGroww Mutual Fund | 4,03,568 | 1.29% | ₹21.7 Cr |
| UTI Healthcare FundUTI Mutual Fund | 3,75,000 | 1.41% | ₹20.2 Cr |
| ICICI Prudential MNC FundICICI Prudential Mutual Fund | 3,31,198 | 1.05% | ₹17.8 Cr |
| Groww Small Cap FundGroww Mutual Fund | 3,02,898 | 1.69% | ₹16.3 Cr |
 ITI Large & Midcap FundITI Mutual Fund | 1,49,459 | 1.16% | ₹8.04 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 1,37,940 | 0.31% | ₹7.42 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Blue Jet Healthcare insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Blue Jet Healthcare competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Blue Jet Healthcare in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Concord BiotechCONCORDBIO | 12,874 | 45.58 | 6.20 | +4.0% | −12.8% | 14.5% | 15.9% | 0.61% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,664 | 39.98 | 3.52 | +9.2% | −14.6% | 9.2% | 12.0% | 0.40% |
 Strides Pharma ScienceSTAR | 10,116 | 16.40 | 2.96 | +11.3% | +55.3% | 20.0% | 13.9% | 0.46% |
 Viyash ScientificVIYASH | 9,917 | – | 3.41 | +96.5% | – | – | 11.2% | 0.00% |
 Procter & Gamble HealthPGHL | 9,152 | 25.64 | 17.45 | – | – | 67.2% | 84.2% | 3.72% |
 Aarti PharmalabsAARTIPHARM | 8,412 | – | 3.73 | +13.4% | – | – | 11.9% | 0.38% |
 Symbiotec PharmalabSYMBIOTEC | 8,033 | – | – | – | – | – | – | 0.00% |
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,987 | 28.56 | 22.96 | +22.7% | +28.4% | 92.5% | 102.5% | 2.16% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Blue Jet Healthcare dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.20 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 11 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.20 |
| 19 Sep 2025 | Final | ₹1.20 |
| 17 Sep 2024 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Blue Jet Healthcare announcements
Oct 2026
29 Oct · Analysts
29 Oct · Board meeting
Sep 2026
21 Sep · Meeting
Aug 2026
Blue Jet Healthcare share price by year
Each calendar year to 2025.Blue Jet Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 530.20 | −6.1% | 1,010.20 | 519.80 |
| 2024 | 564.70 | +53.4% | 580.45 | 330.35 |
| 2023 | 368.10 | – | 413.40 | 322.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 1 Nov 2023.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 494.00 | 521.80 | 488.60 | 517.85 | 512.30 | 3,79,224 | 48.1% |
| 27 Oct 2026 | 485.60 | 499.20 | 481.15 | 495.55 | 493.98 | 2,15,809 | 48.5% |
| 26 Oct 2026 | 475.00 | 490.40 | 470.50 | 485.60 | 483.47 | 1,73,642 | 44.2% |
| 23 Oct 2026 | 490.00 | 490.00 | 462.20 | 475.55 | 472.24 | 7,89,587 | 68.6% |
| 22 Oct 2026 | 493.10 | 501.55 | 485.00 | 487.70 | 490.87 | 2,61,586 | 46.7% |
| 21 Oct 2026 | 509.00 | 511.10 | 490.00 | 495.40 | 496.31 | 2,93,212 | 54.5% |
| 19 Oct 2026 | 523.00 | 526.05 | 505.10 | 507.45 | 512.53 | 2,70,423 | 50.2% |
| 16 Oct 2026 | 519.00 | 523.95 | 516.25 | 520.65 | 519.65 | 1,37,168 | 48.6% |
| 15 Oct 2026 | 525.00 | 527.65 | 516.65 | 519.45 | 522.11 | 2,03,061 | 50.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- BLUEJET
- BSE code
- 544009
- ISIN
- INE0KBH01020
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.bluejethealthcare.com
- CIN
- L99999MH1968PLC014154
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1968
- Registered office
- 701, 702, Bhumiraj Costarica, 7th Floor, Sector 18, Sanpada, Navi Mumbai 400705, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments